Opus Genetics to Participate in Upcoming Investment Conferences
Opus Genetics, Inc. (IRD)
Company Research
Source: GlobeNewswire
RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will participate in the following investor conferences. BTIG 5th Annual Ophthalmology Day (Virtual): Ash Jayagopal, PhD, MBA, Chief Scientific and Development Officer, will participate in a fireside chat on Monday, December 1, 2025, at 1:00 p.m. ET. Piper Sandler 37th Annual Healthcare Conference: George Magrath, M.D., Chief Executive Officer, will participate in a fireside chat on Tuesday, December 2, 2025, at 10:00 a.m. ET in New York, NY. A link to the live and archived webcast for the Piper Sandler conference may be accessed on Opus Genetics’ website under the Investors section: Events. About Opus Genetics Opus Genetics is a clinical-stage biopharmaceut
Show less
Read more
Impact Snapshot
Event Time:
IRD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRD alerts
High impacting Opus Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
IRD
News
- Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026GlobeNewswire
- Opus Genetics (NASDAQ:IRD) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $7.00 price target on the stock.MarketBeat
- Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis PigmentosaGlobeNewswire
- Opus Genetics (NASDAQ:IRD) was upgraded by analysts at BTIG Research to a "strong-buy" rating.MarketBeat
- Opus Genetics (NASDAQ:IRD) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.MarketBeat
IRD
Sec Filings
- 1/26/26 - Form 4
- 1/26/26 - Form 4
- 1/26/26 - Form 4
- IRD's page on the SEC website